Abstract: The present invention provides novel 11-deoxy-19-oxo-PGE.sub.1 compounds, which are useful for a variety of pharmacological purposes, e.g., antiasthmatic indications.

Abstract: The present invention provides novel 11-Deoxy-11-hydroxymethyl-19-oxo-PGF.sub.2 compounds, which are useful for a variety of pharmacological purposes, e.g., antiasthmatic indications.

Abstract: The present invention provides novel 9-deoxy-9-methylene-11-deoxy-11-methylene-19-oxo-PGF.sub.1 compounds, which are useful for a variety of pharmacological purposes, e.g., antiasthmatic indications.

Abstract: The invention disclosed herein relates to pharmacologically active prostaglandin derivatives of the E and F series wherein C-16 is substituted with hydrogen, methyl, vinyl or ethynyl and C-19 substituted with chloro and the .beta.-chain consists of 7 carbon atoms.

Abstract: Prostaglandin E.sub.1 analogues of the general formula: ##STR1## [wherein Y represents ethylene or trans-virylene, Z represents ethylene or trans-vinylene, R.sup.1 represents a hydrogen atom, an alkyl group containing 1 to 12 carbon atoms, an aralkyl group containing from 7 to 12 carbon atoms, a cycloalkyl group containing from 4 to 7 carbon atoms and unsubstituted or substituted by at least one alkyl group containing from 1 to 6 carbon atoms, a phenyl group unsubstituted or substituted by at least one chlorine atom, trifluoromethyl group, alkyl group containing from 1 to 4 carbon atoms or phenyl group, a--C.sub.m H.sub.2m COOR.sup.5 group (wherein m represents an integer of from 1 to 12 and R.sup.5 represents a hydrogen atom or an alkyl group containing from 1 to 4 carbon atoms ), a --C.sub.n H.sub.2n OR.sup.6 group (wherein R.sup.6 represents a hydrogen atom or an alkyl group containing from 1 to 4 carbon atoms and n represents an integer of from 2 to 12), or a ##STR2## group (wherein R.sup.7 and R.sup.

Abstract: The present invention provides novel 11-Deoxy-19-oxo-PGF.sub.2 compounds, which are useful for a variety of pharmacological purposes, e.g., antiasthmatic indications.

Abstract: The present invention provides novel 11-Deoxy-19-oxo-PGE.sub.2 compounds, which are useful for a variety of pharmacological purposes, e.g., antiasthmatic indications.

Abstract: The present invention provides novel 11-Deoxy-11-hydroxymethyl-9-deoxy-9-methylene-19-oxo-PGF.sub.2 compounds, which are useful for a variety of pharmacological purposes, e.g., antiasthmatic indications.

Abstract: The present invention provides novel 19-hydroxy-19-methyl-6-oxo-PGF.sub.1 intermediates for preparing prostacyclin analogs which are useful for pharmacological purposes, e.g., anti-asthmatic indications.

Abstract: The present invention provides novel 19,20-didehydro-PG.sub.1 compounds, methods for their preparation and pharmacological use for the induction of prostaglandin-like effect.

Abstract: The present invention provides novel 19,20-didehydro-13,14-dihydro-PG.sub.1 compounds, methods for their preparation and pharmacological use for the induction of prostaglandin-like effect.

Abstract: The present invention provides novel 19-hydroxy-19-methyl-13,14-dihydro-PG.sub.2 compounds, methods for their preparation and pharmacological use for the induction of prostaglandin-like effect.

Abstract: The present invention provides novel 19-hydroxy-19-methyl-inter-oxa-13,14-dihydro-PG.sub.1 compounds, methods for their preparation and pharmacological use for the induction of prostaglandin-like effect.CROSS REFERENCE TO RELATED APPLICATIONSThe present application is a division of Ser. No. 025,878, filed Apr. 2, 1979, now abandoned.PRIOR ARTProstaglandin analogs exhibiting hydroxylation in the 19-position are known in the art. See, for example, U.S. Pat. No. 4,127,612, Sih, J.C., Prostaglandins 13:831 (1977) and U.S. Pat. Nos. 3,657,316, 3,878,046, and 3,922,297. See also the additional references cited in U.S. Ser. No. 025,878.

Abstract: The present invention provides novel 19-hydroxy-19-methyl-13,14-dihydro-PG.sub.1 compounds, methods for their preparation and pharmacological use for the induction of prostaglandin-like effect.

Abstract: The present invention provides novel 19-hydroxy-cis-4,5-didehydro-13,14-dihydro-PG.sub.1 Analogs methods for their preparation and pharmacological use for the induction of prostaglandin-like effect.

Abstract: 4,5-Unsaturated 16-hydroxy prostanoic acid derivatives displaying valuable pharmacological properties, e.g. gastric antisecretory, are described herein.

Abstract: The present invention provides novel 19-hydroxy-cis-4,5-didehydro-PG.sub.1 analogs methods for their preparation and pharmacological use for the induction of prostaglandin-like effect.

Abstract: The invention discloses certain novel 13,14-dihydro-15-alkenyl prostaglandins and 13,14-dihydro-15-alkynyl prostaglandins and analogs of each as well as the novel intermediates employed in their preparation. The 9-oxo compounds of this novel series demonstrate selective bronchodilator activity, certain of these are also useful as antisecretory agents.

Abstract: The present invention provides novel 19-hydroxy-19-methyl-cis-4,5-didehydro-13,14-dihydro-PG.sub.1 compounds, methods for their preparation and pharmacological use for the induction of prostaglandin-like effect.

Abstract: The present invention provides novel 19-hydroxy-19-methyl-trans-2,3-didehydro-13,14-dihydro-PG.sub.1 compounds, methods for their preparation and pharmacological use for the induction of prostaglandin-like effect.

Abstract: The present invention provides novel 19-hydroxy-19-methyl-inter-oxa-PG.sub.1 compounds, methods for their preparation and pharmacological use for the induction of prostaglandin-like effect.

Abstract: The present invention provides novel 19-hydroxy-19-methyl-trans-2,3-didehydro-PG.sub.1 compounds, methods for their preparation and pharmacological use for the induction of prostaglandin-like effect.

Abstract: This disclosure describes certain 11-hydroxy and 11-deoxy-1-ketocarboxylic acid prostanoic acids and derivatives useful as bronchodilators, hypotensive agents, anti-ulcer agents or intermediates.

Abstract: This disclosure describes certain 11-hydroxy and 11-deoxy-1-ketocarboxylic acid prostanoic acids and derivatives useful as bronchodilators, hypotensive agents, anti-ulcer agents or intermediates.

Abstract: The present invention provides novel 19-hydroxy-19-methyl-cis-4,5-didehydro-PG.sub.1 compounds, methods for their preparation and pharmacological use for the induction of prostaglandin-like effect.

Abstract: The 16-substituted 15-hydroxy prostaglandins which are saturated at the 13-position and the 16-substituted-15-keto prostaglandins, said prostaglandins being useful as antisecretory agents, blood pressure lowering agents, anti-ulcerogenic agents and antihypertensive agents.

Abstract: The present invention provides novel 19-hydroxy-inter-oxa-PG.sub.1 compounds methods for their preparation and pharmacological use for the induction of prostaglandin-like effect.

Abstract: The present invention provides novel 19-hydroxy-6-oxo-PGF.sub.1 intermediates for preparing prostacyclin analogs which are useful for pharmacological purposes, e.g., anti-asthmatic indications.

Abstract: The present invention provides novel 19-hydroxy-13,14-dihydro-PG.sub.2 compounds methods for their preparation and pharmacological use for the induction of prostaglandin-like effect.

Abstract: This invention provides new mono-deuterated prostaglandins having prolonged uterotonic activity.

Abstract: The present invention provides novel 19-hydroxy-trans-2,3-didehydro-13,14-dihydro-PG.sub.1 compounds methods for their preparation and pharmacological use for the induction of prostaglandin-like effect.

Abstract: The present invention provides novel 19-hydroxy-inter-oxa-13,14-dihydro-PG.sub.1 compounds methods for their preparation and pharmacological use for the induction of prostaglandin-like effect.

Abstract: The present invention provides novel 19-hydroxy-13,14-dihydro-PG.sub.1 compounds methods for their preparation and pharmacological use for the induction of prostaglandin-like effect.

Abstract: The present invention relates to novel prostaglandin derivatives of the formula I ##STR1## which are structurally related to the naturally occurring prostaglandins and in which R.sup.1 denotes (a) hydrogen or a straight-chain or branched, saturated or unsaturated aliphatic or cycloaliphatic hydrocarbon radical having up to ten carbon atoms or (b) a physiologically acceptable metal or NH.sub.4 ion or an ammonium ion which is derived from a primary, secondary or tertiary amine and R.sup.2 denotes a straight-chain, aliphatic hydrocarbon radical having up to six carbon atoms and to a process for their manufacture.The compounds of the invention are distinguished in particular by gastric acid secretion-inhibiting and ulcer-protective properties.

Abstract: The present invention provides novel 19-hydroxy PG.sub.2 analogs, methods for their preparation and pharmacological use for the induction of prostaglandin-like effect.

Abstract: The present invention provides novel 19-hydroxy-trans-2,3-didehydro-PG.sub.1 compounds methods for their preparation and pharmacological use for the induction of prostaglandin-like effect.

Abstract: This disclosure describes certain 11-hydroxy and 11-deoxy-1-ketocarboxylic acid prostanoic acids and derivatives useful as bronchodilators, hypotensive agents, anti-ulcer agents or intermediates.

Abstract: This disclosure describes certain 11-hydroxy and 11-deoxy-1-ketocarboxylic acid prostanoic acids and derivatives useful as bronchodilators, hypotensive agents, anti-ulcer agents or intermediates.

Abstract: The present invention relates to new analogues which do not occur naturally of prostanoic acids of the formula I ##STR1## The compounds of the invention have spasmogenic, bronchodilatant and hypotensive properties. Therefore, they can be used as medicaments.This invention also relates to a process for preparing the compounds of the invention.

Abstract: This disclosure describes certain 11-hydroxy and 11-deoxy-1-ketocarboxylic acid prostanoic acids and derivatives useful as bronchodilators, hypotensive agents, anti-ulcer agents or intermediates.

Abstract: This disclosure describes certain 11-hydroxy and 11-deoxy-1-ketocarboxylic acid prostanoic acids and derivatives useful as bronchodilators, hypotensive agents, anti-ulcer agents or intermediates.

Abstract: N-substituted .omega.-aminoalkanoyl-.omega.-aminoalkanoic acids and their pharmacologically-acceptable salts (with a base) are useful, e.g., in pharmaceutical-composition form for the treatment or prophylaxis of diseases which are based on inadequate performance of the pancreas, the bile and/or the liver. The compounds are prepared, e.g., by reacting an N-(mono- or di-substituted) .omega.-amino-alkanoic acid with an N-(unsubstituted or monosubstituted) .omega.-aminoalkanoic acid.

Abstract: The invention described herein relates to novel 15-deoxy-16-hydroxy-16-ethynyl or 16-(1-propynyl) prostaglandins of E, F, D and A series having on the terminal methylene carbon of the alpha chain a substituent selected from the group consisting of: ##STR1## wherein R.sub.1 is selected from the group consisting of hydrogen and C.sub.1 -C.sub.6 alkyl; R.sub.15 is selected from the group consisting of C.sub.1 -C.sub.4 alkyl, di-C.sub.1 -C.sub.4 -alkylamino, phenyl and phenyl substituted with one or more substituents selected from the group consisting of C.sub.1 -C.sub.4 alkyl, OR, SR, F or Cl, wherein R is an alkyl group.

Abstract: 11-Substituted prostaglandins E.sub.1, E.sub.2 and F.sub.2.alpha. useful as cardiovascular agents and as agents for inducing labor in pregnant females and for the termination of pregnancy and a process for preparing these prostaglandins.

Abstract: An improved method for synthesizing and purifying PGB.sub.x, a mixture of lymers of prostaglandin B.sub.1. PGB.sub.x activity is assayed by measuring the minimum amount of PGB.sub.x required to restore complete phosphorylation ability to isolated rat liver mitochondria, first aged and degraded to the point where they exhibit less than 5% of the phosphorylating ability of normal mitochondria. A higher and more reproducible yield of PGB.sub.x of improved quality have been produced thereby.

Abstract: This disclosure describes derivatives, analogs, and congeners of prostanoic acid having a terminal cyclic moiety in the .beta.-chain which possess the pharmacological activities associated with the prostaglandins.

Abstract: Prostaglandin derivatives having a 19,20-didehydro, a 19-hydroxy, or a 19-keto feature are disclosed, including processes for preparing them and the appropriate intermediates.A typical 19-hydroxy compound of this invention is 19-hydroxy-19-methyl-PGF.sub.2.alpha.

Abstract: Novel azaprostanoic acid analogs of the formula ##STR1## wherein: R is C.sub.1 to C.sub.8 alkyl or benzyl; and a has a value of from 0 to 6 inclusive, and their pharmaceutically acceptable salts and esters. Preferred 13-aza and 15-aza compounds are active in the inhibition of arachidonic acid-induced platelet aggregation and, more specifically, are direct and specific antagonists of the activity of prostaglandin H.sub.2 and thromboxane A.sub.2.

Abstract: 15-Deoxy-16-hydroxy-16-ethynyl and 16-ethynylsubstituted prostanoic acids and congeners thereof, useful as bronchodilators, hypotensive agents, and as agents for the control of excessive gastric secretion.

Abstract: The inventions disclosed herein relates to pharmacologically active .DELTA.19 prostaglandins of the E and F series in which C-16 is substituted with hydroxyl and methyl as well as the pharmacologically acceptable, non toxic lower alkyl esters and salts thereof, and to the intermediates and processes for producing such compounds.